ELTX Stock — Elicio Therapeutics Inc.: Cash, EV, Pipeline

Share price

$1.89

Market cap

$49.7M

Cash

$37.1M

Enterprise value

$22.2M

Balance sheet

Cash	$37.1M
Debt	$9.5M
Net cash	$27.5M
Enterprise value	$22.2M
Basic shares	21.9M shares
Fully diluted shares	33.0M shares
Fully diluted market cap	$62.3M
Cash per share	$1.69

Cash figures as of 2026-07-06. Database snapshot: 2026-09-21.

Price history

Loading ELTX daily closes…

Loading price history…

Pipeline assets

ELI-002 7P

Phase 2 · Active Modality: lymph node-targeted cancer immunotherapy (Amphiphile/AMP)

Target mKRAS (7 KRAS mutations)

Partnerships MIT (license)

Indications

adjuvant mKRAS-driven pancreatic ductal adenocarcinoma (Phase 2)
mKRAS-positive cancers (Phase 2)

Status note AMPLIFY-7P Phase 2 failure reported June 2026; company evaluating pre-specified subgroups and refining Phase 3 strategy; no discontinuation disclosed.

ELI-002 2P

Phase 1 · Active Modality: lymph node-targeted cancer immunotherapy (Amphiphile/AMP)

Target mKRAS

Partnerships MIT (license)

Indications

mKRAS-driven solid tumors (PDAC, CRC) (Phase 1)

Status note Studied in Phase 1 AMPLIFY-201; no discontinuation disclosed.

ELI-007

Preclinical · Active Modality: lymph node-targeted immunotherapy

Target mutant BRAF

Partnerships MIT (license)

Indications

mutant BRAF-driven cancers (Preclinical)

Status note Preclinical; no discontinuation disclosed.

ELI-008

Preclinical · Active Modality: lymph node-targeted immunotherapy

Target mutant p53

Partnerships MIT (license)

Indications

mutant p53-expressing cancers (Preclinical)

Status note Preclinical; no discontinuation disclosed.

Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	ELI-002 7P
Lead indication	Pancreatic Ductal Adenocarcinoma
Lead phase	Phase 1/2
Active trials	1
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05726864	Phase 1/2	Active, not recruiting	Sponsor	Elicio Therapeutics	—	Pancreatic Ductal Adenocarcinoma; Colorectal Cancer; KRAS G12D	—
NCT07671339	Phase 1	Recruiting	Collaborator	Memorial Sloan Kettering Cancer Center	—	Pancreatic Cancer	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Elicio Therapeutics on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Ikarian Capital	100,000	+100,000	0.06%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

ELTX — Elicio Therapeutics Inc.

Balance sheet

Price history

Pipeline assets

Pipeline

Active clinical trials

Institutional holders